XCOPRI efficacy and prescribing overview

Summarizes the efficacy data of XCOPRI. Includes an example prescription schedule, as well as guidance on how to prescribe.

XCOPRI Efficacy and Prescribing Overview Screenshot

Managing adjunctive use of XCOPRI flashcard

Highlights important information for getting patients started on XCOPRI and the dose adjustments that may be needed when prescribing XCOPRI concomitantly with certain medications.

Managing Adjunctive Use of XCOPRI Flashcard

Getting patients started on XCOPRI

Designed to assist healthcare professional office staff in initiating patients on XCOPRI. This resource provides comprehensive guidance on XCOPRI cost and coverage, prescribing information, and insights into the extensive support programs for both office staff and patients.

What to Expect When Taking XCOPRI PDF Screenshot

Get your patients started on XCOPRI today


Patient brochure

This brochure helps your patients understand what to expect from treatment. Includes information on how to take XCOPRI, potential side effects, and a patient-friendly version of the data from the clinical trials.

XCOPRI Patient Brochure

Caregiver brochure

Caregivers play an important role in the fight against partial-onset seizures. This brochure helps caregivers understand how to take care of themselves while also taking care of their loved one.

XCOPRI Caregiver Brochure

S.T.E.P.S.—a discussion guide
for patients with epilepsy

Standing for Seizures, Treatments, Emotional Impact, Personal Goals, and Safety—the Discussion Guide was designed to help foster a stronger relationship between patients and their care teams, and help those affected by epilepsy reach their goals.

The guide is based on a national survey that compiled responses from 400 adult patients, 201 caregivers, and 258 healthcare providers to help better understand the current state of epilepsy in the US.

XCOPRI S.T.E.P.S. - A Discussion Guide for Patients with Epilepsy

Trial offer: Introduce your eligible patients to XCOPRI for free



XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients.

Important Safety Information
and indication

XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

For US Healthcare Professionals Only



XCOPRI® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.


Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.


In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.


Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

  • Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
  • Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
  • Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
  • Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment


XCOPRI is a Schedule V controlled substance.


XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.